On May 15, 2026, Germany’s Medical Products Sustainability Act (MedSusG) entered into force, mandating verified lifecycle carbon footprint reporting for all imported medical devices. Products exceeding defined thresholds—such as CT scanners at ≥12.5 t CO₂e—will be denied customs clearance. This regulation directly affects manufacturers and exporters of high-end medical imaging and in vitro diagnostic equipment, particularly those based in China, and has drawn attention from the European Commission, which is considering integrating similar requirements into the upcoming revision of the EU Medical Device Regulation (MDR).

Event Overview

The Medical Products Sustainability Act (MedSusG) became effective in Germany on May 15, 2026. Under the law, all imported medical devices must submit a full lifecycle carbon footprint report, verified by an accredited third party. Devices exceeding specified carbon thresholds—including 12.5 metric tons of CO₂-equivalent for computed tomography (CT) systems—are prohibited from entering German customs. The European Commission has acknowledged the regulation and is preparing to include comparable provisions in its draft revision of the EU Medical Device Regulation (MDR).

Industries Affected

Direct Exporters and Trade Enterprises

Companies exporting medical devices to Germany—especially those supplying advanced imaging or laboratory diagnostics equipment—face immediate compliance obligations. Non-compliance results in shipment rejection at customs, disrupting delivery schedules and contractual commitments. The requirement applies regardless of device class or CE marking status, adding a new layer of pre-market administrative and technical validation.

Original Equipment Manufacturers (OEMs) and Contract Manufacturers

OEMs producing devices for export to Germany must now integrate carbon accounting into product development and documentation workflows. This includes defining system boundaries, collecting upstream material and energy data, and coordinating with suppliers for primary emission factors. For contract manufacturers, liability may extend to supporting clients’ verification submissions—even if they do not hold the regulatory authorization.

Supply Chain and Component Suppliers

Suppliers of critical subsystems (e.g., X-ray tubes, detector modules, or reagent kits) may be asked to provide verified environmental data to enable downstream footprint calculations. While not directly regulated under MedSusG, their responsiveness and data transparency will influence OEMs’ ability to meet reporting deadlines and thresholds.

Distribution and Regulatory Affairs Service Providers

Regulatory consultancies, Notified Bodies offering sustainability verification, and logistics firms handling German-bound shipments must adapt service offerings. Demand is rising for support in carbon footprint methodology alignment (e.g., ISO 14040/44, EN 15804), verification coordination, and customs documentation integration—yet no standardized format for submission has been published by German authorities as of the law’s entry into force.

What Relevant Enterprises or Practitioners Should Focus On and How to Respond

Monitor official guidance and MDR revision timelines

Analysis shows that the German Federal Institute for Drugs and Medical Devices (BfArM) has not yet published detailed implementation rules—including accepted calculation methodologies, verification scope, or transitional arrangements. Concurrently, the European Commission’s planned MDR revision remains in early drafting stages; its final scope and timeline are pending. Stakeholders should track updates from BfArM, the European Commission’s Health and Food Safety Directorate-General (SANTE), and notified bodies accredited for sustainability verification.

Prioritize high-risk product categories and export lanes

Observably, CT systems, MRI scanners, PET-CT hybrids, and high-throughput clinical analyzers face the highest risk due to both explicit threshold references and their energy- and material-intensive manufacturing profiles. Companies should first map German-bound SKUs against the published thresholds and assess whether existing LCA studies—or supplier-provided data—meet MedSusG’s verification requirements. Parallel review of other EU markets (e.g., France’s forthcoming eco-modulation schemes) is also advisable, though MedSusG currently applies only to Germany.

Distinguish policy signal from operational enforcement

Current more appropriately reflects a regulatory signal than a fully enforced regime: while the law is legally in effect, customs authorities have not yet reported systematic carbon-based rejections, and no public list of approved verifiers exists. Enterprises should treat initial submissions as pilot engagements—not assume full-scale enforcement begins immediately—but recognize that capacity-building (e.g., staff training, LCA tool licensing, verifier engagement) cannot wait until enforcement escalates.

Prepare documentation, supplier engagement, and internal alignment now

From industry perspective, carbon footprint reporting requires cross-functional coordination: R&D (for bill-of-materials and process energy data), procurement (for supplier emission disclosures), quality (for documentation control), and regulatory affairs (for submission oversight). Companies should initiate internal gap assessments, identify data gaps per ISO 14067 or Product Environmental Footprint (PEF) Category Rules, and begin supplier outreach—particularly for components sourced outside the EU—well ahead of anticipated audit or submission windows.

Editorial Perspective / Industry Observation

This regulation is better understood as a leading-edge policy signal rather than an isolated national measure. Analysis shows it reflects a broader institutional shift within the EU toward embedding climate criteria into sectoral product regulations—not just energy efficiency or recyclability, but full lifecycle emissions. Its inclusion in the upcoming MDR revision draft suggests convergence is likely, though timing and harmonization level remain uncertain. Observably, MedSusG does not introduce new environmental performance standards per se, but rather activates a gatekeeping mechanism: carbon data becomes a prerequisite for market access, not merely a sustainability disclosure. For global medical device stakeholders, this marks the beginning of a new compliance dimension—one where environmental data infrastructure carries the same weight as clinical evidence or cybersecurity documentation.

Germany’s Medical Products Sustainability Act signals the formal integration of carbon accountability into medical device market access—not as voluntary ESG reporting, but as a binding, enforceable condition. Its immediate impact is procedural and jurisdictional (limited to German imports), yet its long-term significance lies in precedent-setting: it tests the feasibility of applying product-level carbon thresholds across complex, globally distributed health technology supply chains. Current interpretation should emphasize preparedness over panic—recognizing that robust carbon data governance, once established, supports broader regulatory resilience, not just MedSusG compliance.

Source: Official announcement of the Medical Products Sustainability Act (MedSusG) by the German Federal Ministry of Health; public statements from the European Commission’s Health and Food Safety Directorate-General (SANTE); confirmed effective date and threshold values as published in the Bundesgesetzblatt (Federal Law Gazette) Part I, No. 27, May 15, 2026.
Note: Implementation guidelines, verifier accreditation lists, and MDR revision text remain under development and require ongoing monitoring.